We provide the scientific and technical capability to ensure Seqirus products are among the best defences against influenza in the world
Seqirus draws on the experience of our parent company CSL, which has been developing influenza vaccines for over 100 years, as well as antivenoms and other vaccines. Our quadrivalent and MF59®-adjuvanted influenza vaccines reach more and more patients every year.
In 2017, Seqirus released an advanced cell-based influenza vaccine in the USA and achieved FDA approval for the next generation production process for cell-based technology. Each and every flu season, we use our deep technical expertise to ensure our technology platforms, are performing at their best.
Optimising vaccine viruses
We evaluate and optimise candidate vaccine viruses from the WHO to speed up production and improve vaccine match. It is a constant process, as we manufacture a new formulation of influenza vaccine every six months.
Improvement of manufacturing technology
The flu virus changes all the time. We aim to stay ahead. Our scientists continuously improve and enhance the manufacturing and testing of our existing products, whilst pioneering the development of new products.Learn more
Technical Development at Seqirus is Global
Our technical development teams are located with our manufacturing operations on three different continents, united as one global organisation.
Studying the potential of cell
Are you more like a bird than a mammal? We didn’t think so either. Our entirely cell based influenza vaccine may offer a closer match to circulating flu virus than egg-based influenza vaccines in some seasons . More research is underway.
Boosting flu response
Older adults don’t respond as well to the standard influenza vaccine. Don’t worry! We developed an adjuvanted influenza vaccine, now a recommended choice for the people over 65 years of age in Australia.
Our global development group is working to make influenza vaccines that are more effective for all ages and easier to manufacture and deliver to our customers.
SEQ/CORP/1019/0027 October 2019